Holen Sie sich die Stockscreener-App
16.14
12.32%
1.77
Handel nachbörslich:
16.20
0.06
+0.37%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt KVUE?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$14.37
Offen:
$17.065
24-Stunden-Volumen:
204.02M
Relative Volume:
6.24
Marktkapitalisierung:
$30.97B
Einnahmen:
$15.14B
Nettoeinkommen (Verlust:
$1.42B
KGV:
21.93
EPS:
0.7361
Netto-Cashflow:
$1.63B
1W Leistung:
+7.03%
1M Leistung:
+2.09%
6M Leistung:
-32.69%
1J Leistung:
-28.99%
1-Tages-Spanne:
$16.14
$17.18
1-Wochen-Bereich:
$14.02
$17.18
52-Wochen-Spanne:
$14.02
$25.17
Kenvue Inc Stock (KVUE) Company Profile
Firmenname
Kenvue Inc
Sektor
Telefon
908-874-1200
Adresse
1 KENVUE WAY, SUMMIT
Vergleichen Sie KVUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KVUE
Kenvue Inc
|
16.14 | 27.58B | 15.14B | 1.42B | 1.63B | 0.7361 |
|
PG
Procter Gamble Co
|
148.02 | 351.37B | 84.93B | 16.86B | 14.94B | 6.8506 |
|
UL
Unilever Plc Adr
|
60.67 | 147.58B | 64.99B | 6.71B | 6.53B | 2.4355 |
|
CL
Colgate Palmolive Co
|
74.98 | 62.11B | 20.10B | 3.04B | 3.37B | 3.569 |
|
KMB
Kimberly Clark Corp
|
102.27 | 39.73B | 18.08B | 1.81B | 2.10B | 5.904 |
Kenvue Inc Stock (KVUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-09-26 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-04-10 | Eingeleitet | Redburn Atlantic | Neutral |
| 2025-03-24 | Eingeleitet | Evercore ISI | In-line |
| 2025-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-09-24 | Eingeleitet | Jefferies | Buy |
| 2024-09-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-28 | Fortgesetzt | Citigroup | Neutral |
| 2024-04-11 | Eingeleitet | Bernstein | Underperform |
| 2024-04-03 | Eingeleitet | William Blair | Mkt Perform |
| 2024-03-01 | Fortgesetzt | Goldman | Neutral |
| 2023-11-17 | Eingeleitet | Piper Sandler | Neutral |
| 2023-09-11 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-09-07 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-09-06 | Eingeleitet | Argus | Hold |
| 2023-08-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-25 | Eingeleitet | Edward Jones | Buy |
| 2023-06-01 | Eingeleitet | HSBC Securities | Hold |
| 2023-05-30 | Eingeleitet | BofA Securities | Buy |
| 2023-05-30 | Eingeleitet | Citigroup | Neutral |
| 2023-05-30 | Eingeleitet | Deutsche Bank | Hold |
| 2023-05-30 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2023-05-30 | Eingeleitet | Goldman | Neutral |
| 2023-05-30 | Eingeleitet | JP Morgan | Overweight |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Eingeleitet | UBS | Neutral |
Alle ansehen
Kenvue Inc Aktie (KVUE) Neueste Nachrichten
Why Tylenol Maker Kenvue Stock Just Popped - AOL.com
Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc.KVUE - The AI Journal
Buy Rating on Kenvue, Inc.: Promising Investment Amid Acquisition and Legal Challenges - TipRanks
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient' - CNBC
Factbox-Kenvue’s legal risks loom over planned acquisition by Kimberly-Clark - Yahoo Finance
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm - The New York Times
Factbox-Kenvue’s Legal Risks Loom Over Planned Acquisition by Kimberly-Clark - US News Money
Kimberly-Clark acquires Neutrogena-owner KenvueFashionNetwork - FashionNetwork - The World's Fashion Business News
Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue - The Wall Street Journal
Markets News, Nov. 3, 2025: Dow Falters as Cloud Deals Boost Nasdaq; Kenvue Stock Soars on Kimberly-Clark Takeover - Investopedia
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Kenvue Inc. - 富途牛牛
Kenvue: Takeover by Kimberly-Clark Gives Shareholders a Lifeline - Morningstar
Reports of ‘Click-to-Cancel’s Death May Be Premature - PYMNTS.com
Kenvue, Kimberly-Clark, Amazon, uniQure, Palantir, Idexx, Cipher Mining, and More Movers - Barron's
S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue - Investopedia
Kenvue To Be Acquired by Kimberly-Clark To Create a Personal Care Giant - Morningstar
Kimberly-Clark to Buy Tylenol Maker Kenvue. Why KMB Stock Is Tanking. - Barron's
Dear Kenvue Stock Fans, Mark Your Calendars for November 6 Upcoming earnings - Barchart.com
That $40 Billion Tylenol Deal Is Both Cheap and Risky - Bloomberg.com
Kimberly-Clark to Buy Tylenol Maker Kenvue for $40 Billion - Bloomberg.com
The Key Question Around The Kenvue/Kimberly-Clark Tie-Up (NYSE:KVUE) - Seeking Alpha
Kenvue jumps after Kimberly‑Clark announces $48.7B acquisition - Quiver Quantitative
Kenvue could see interest from other suitorsanalyst (KVUE:NYSE) - Seeking Alpha
Kimberly-Clark buying Tylenol-maker Kenvue in cash, stock deal worth about $48.7B - ABC7 Chicago
Huggies maker Kimberly-Clark is buying Tylenol maker KenvueOregon Public Broadcasting - Oregon Public Broadcasting - OPB
Irving-based Kimberly-Clark buys Tylenol maker Kenvue in $48.7 billion deal - Dallas News
Kimberly-Clark to buy Kenvue for $40 billion - Ad Age
Kimberly-Clark buys Tylenol-maker Kenvue in $48.7 billion deal - The Spokesman-Review
How Tylenol Owner’s Short Stint as a Public Company Ended - Bloomberg.com
Kimberly-Clark to buy Tylenol maker Kenvue for $40bn - Al Jazeera
Kenvue Stock Pops on News Kimberly-Clark Will Buy It for $48.7B. Is It Too Late to Buy KVUE Here? - Yahoo Finance
What we know about Kimberly-Clark acquiring the maker of Tylenol - Deseret News
Kimberly-Clark makes a $49 billion bet that Tylenol risk is overblown - Yahoo Finance
Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger - Yahoo Finance
Kenvue Inc. Reaffirms Earnings Guidance for the Full Year 2025 - MarketScreener
Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday - Benzinga
Kimberly-Clark bets $40 billion on Kenvue despite Tylenol controversy - Yahoo Finance
Kimberly-Clark bets $40 billion for Kenvue despite Tylenol controversy - MSN
Is Kenvue’s Stock Ready for a Rebound? - StocksToTrade
Kimberly-Clark to Acquire Tylenol Maker Kenvue in $49 Billion Deal - D Magazine
Kimberly-Clark to Acquire Kenvue in US$48.7 Billion Merger - Mexico Business News
What is Kenvue? What to know about the maker of Tylenol acquired by Kimberly-Clark - Dallas News
Kenvue Acquisition Boosts Kimberly-Clark Growth; Mahoning Valley Philanthropists to Be Honored - Business Journal Daily
Bloomberg Intelligence: Kimberly-Clark to Buy Tylenol Maker Kenvue for $40 Billion - Bloomberg.com
Why Kimberly-Clark (KMB) Stock Is Nosediving - Yahoo Finance
Kenvue: Q3 Earnings Snapshot - CTPost
Nvidia, Amazon Extend Rally, Bitcoin Sinks To $107,000: What's Moving Markets Monday? - Benzinga
Drug giant hit by Trump autism claims bought for record $49bn - Yahoo Finance
Kimberly-Clark Corporation (KMB) Stock: Drops Amid $48.7 Billion Acquisition of Kenvue - parameter.io
Kimberly-Clark Corporation Stock (KMB) Opinions on Kenvue Acquisition - Quiver Quantitative
Top Stock Movers Now: Amazon, Kenvue, Kimberly-Clark, Beyond Meat, and More - Yahoo Finance
Finanzdaten der Kenvue Inc-Aktie (KVUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
14.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):